- Home
- DVAX vs BILI Comparison
DVAX vs BILI Comparison
Compare DVAX & BILI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- BILI
- Stock Information
- Founded
- DVAX 1996
- BILI 2009
- Country
- DVAX United States
- BILI China
- Employees
- DVAX N/A
- BILI N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- BILI EDP Services
- Sector
- DVAX Health Care
- BILI Technology
- Exchange
- DVAX Nasdaq
- BILI Nasdaq
- Market Cap
- DVAX 1.3B
- BILI 8.8B
- IPO Year
- DVAX 2004
- BILI 2018
- Fundamental
- Price
- DVAX $9.75
- BILI $27.08
- Analyst Decision
- DVAX Buy
- BILI Buy
- Analyst Count
- DVAX 4
- BILI 6
- Target Price
- DVAX $26.50
- BILI $26.00
- AVG Volume (30 Days)
- DVAX 2.0M
- BILI 4.1M
- Earning Date
- DVAX 11-06-2025
- BILI 11-13-2025
- Dividend Yield
- DVAX N/A
- BILI N/A
- EPS Growth
- DVAX N/A
- BILI N/A
- EPS
- DVAX N/A
- BILI 0.07
- Revenue
- DVAX $316,268,000.00
- BILI $4,101,275,719.00
- Revenue This Year
- DVAX $23.23
- BILI $14.58
- Revenue Next Year
- DVAX $16.57
- BILI $8.92
- P/E Ratio
- DVAX N/A
- BILI $371.50
- Revenue Growth
- DVAX 26.66
- BILI 22.70
- 52 Week Low
- DVAX $9.20
- BILI $14.47
- 52 Week High
- DVAX $14.63
- BILI $31.77
- Technical
- Relative Strength Index (RSI)
- DVAX 43.66
- BILI 65.74
- Support Level
- DVAX $9.20
- BILI $23.70
- Resistance Level
- DVAX $9.94
- BILI $28.20
- Average True Range (ATR)
- DVAX 0.31
- BILI 0.75
- MACD
- DVAX -0.01
- BILI 0.48
- Stochastic Oscillator
- DVAX 50.00
- BILI 81.88
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About BILI Bilibili Inc.
Bilibili is a Chinese online entertainment platform best known for its YouTube-like video-sharing site. Founded in 2009, it initially focused on long-form content centered around anime, comics, and gaming, catering primarily to Gen Z users. Over time, the platform has broadened its content offerings to include a wider range of interests, successfully attracting a more diverse audience beyond the Gen Z demographic.